Emerging treatment options for myelofibrosis: focus on pacritinib

References

• Abdel-WahabOILevineRLPrimary myelofibrosis: update on definition, pathogenesis, and treatmentAnnu Rev Med20096023324518947294
   PubMed Web of Science ®Google Scholar
• TamCSNussenzveigRMPopatUThe natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasmsBlood200811251628163718566326
   PubMed Web of Science ®Google Scholar
• GuptaVFoltzLSirhanSBusqueLTurnerAREmerging therapeutic options for myelofibrosis: a Canadian perspectiveAm J Blood Res20122317018623119228
   PubMedGoogle Scholar
• CervantesFPassamontiFBarosiGLife expectancy and prognostic factors in the classis BCR/ABL-negative myeloproliferative disordersLeukemia200822590591418385755
   PubMed Web of Science ®Google Scholar
• MehtaJWangHIqbalSUMesaREpidemiology of myeloproliferative neoplasms in the United StatesLeuk Lymphoma201455359560023768070
   PubMed Web of Science ®Google Scholar
• TefferiACME information: primary myelofibrosis: 2014 update on diagnostic, risk-stratification and managementAm J Hematol201489991592525124313
   PubMed Web of Science ®Google Scholar
• CervantesFDupriezBPereiraANew prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and TreatmentBlood2009113132895290118988864
   PubMed Web of Science ®Google Scholar
• PassamontiFCervantesFVannucchiAMA dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)Blood201011591703170820008785
   PubMed Web of Science ®Google Scholar
• GangatNCarmazzaDVaidyaRDIPSS plus: a refined dynamic International Prognositc Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion statusJ Clin Oncol201029439239721149668
   PubMed Web of Science ®Google Scholar
• CaramazzaDBegnaKHGangatNRefined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patientsLeukemia2011251828820944670
   PubMed Web of Science ®Google Scholar
• GuglielmelliPLashoTLRotunnoGThe number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patientsLeukemia20142891804181024549259
   PubMed Web of Science ®Google Scholar
• TefferiALashoTLFinkeCMCALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisonsLeukemia20142871472147724402162
   PubMed Web of Science ®Google Scholar
• TefferiALashoTTischerAThe prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variantsBlood2014123152465246625301336
   PubMed Web of Science ®Google Scholar
• ZhouAOhSTPrognostication in MF: from CBC to cytogenetics to molecular markersBest Pract Res Clin Haematol201427215516425189726
   PubMed Web of Science ®Google Scholar
• BallenKKShresthaSSobocinskiKAOutcome of transplantation for myelofibrosisBiol Blood Marrow Transplant201016335836719879949
   PubMed Web of Science ®Google Scholar
• KrögerNHollerEKobbeGAllogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationBlood2009114265264527019812383
   PubMed Web of Science ®Google Scholar
• KrogerNGioginoTScottBLImpact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosisBlood2015125213347335025784679
   PubMed Web of Science ®Google Scholar
• GowinKMesaREmerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosisExpert Opin Investig Drugs2013221216031611
   PubMed Web of Science ®Google Scholar
• CervantesFHow I treat myelofibrosisBlood2014124172635264225232060
   PubMed Web of Science ®Google Scholar
• GeyerHLMesaRATherapy for myeloproliferative neoplasms: when, which agent, and how?Blood2014124243529353725472969
   PubMed Web of Science ®Google Scholar
• TefferiAMesaRANagorneyDMSchroederGSilversteinMNSplenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patientsBlood20009572226223310733489
   PubMed Web of Science ®Google Scholar
• Martinez-TrillosAGayaAMaffioliMEfficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patientsAnn Hematol201089121233123720567824
   PubMed Web of Science ®Google Scholar
• HuangJTefferiAErythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin levelEur J Haematol200983215415519366369
   PubMed Web of Science ®Google Scholar
• CervantesFAlvarez-LarránADomingoAArellano-RodrigoEMontserratEEfficacy and tolerability of danazol as a treatment for the anemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patientsBr J Haematol2005129677177515953003
   PubMed Web of Science ®Google Scholar
• TefferiAPassamontiFBarbuiTPhase 3 study of pomalidomide in myeloproliferative neoplasm (MPN)–associated myelofibrosis with RBC-transfusion dependence [abstract]Blood20131222139423687088
   PubMed Web of Science ®Google Scholar
• TamCSVerstovsekSInvestigational Janus kinase inhibitorsExpert Opin Investig Drugs2013226687699
   PubMed Web of Science ®Google Scholar
• GotlibJJAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedsideHematol Am Soc Hematol Educ Program20132013529537
   PubMed Web of Science ®Google Scholar
• MascarenhasJOCrossNCMesaRAThe future of JAK inhibition in myelofibrosis and beyondBlood Rev201428518919625043171
   PubMed Web of Science ®Google Scholar
• TefferiAVaidyaRCaramazzaDFinkeCLashoTPardananiACirculating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling studyJ Clin Oncol201129101356136321300928
   PubMed Web of Science ®Google Scholar
• VerstovsekSMesaRAGotlibJA double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisN Engl J Med2012366979980722375971
   PubMed Web of Science ®Google Scholar
• HarrisonCKiladijianJJAl-AliHKJAK inhibition with ruxolitinib versus best available therapy for meylofibrosisN Engl J Med2012366978779822375970
   PubMed Web of Science ®Google Scholar
• VerstovsekSMesaRAGotlibJEfficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-IHaematologica201398121865187124038026
   PubMed Web of Science ®Google Scholar
• CervantesFVannucchiMKildadjianJJThree-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosisBlood2013122254047405324174625
   PubMed Web of Science ®Google Scholar
• PassamontiFMaffioliMCervantesFImpact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohortsBlood2014123121833183524443442
   PubMed Web of Science ®Google Scholar
• JungCWRuxolitinib changes the natural course of myelofibrosis and its transplant outcomeBlood Res2013481686923589801
   PubMedGoogle Scholar
• Parampalli YajnanarayanaSStübigTCornezIJAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasmsBr J Haematol2015169682483325824483
   PubMed Web of Science ®Google Scholar
• SchönbergKRudolphJVonnahmeMJAK inhibition impairs NK cell function in myeloproliferative neoplasmsCancer Res201575112187219925832652
   PubMed Web of Science ®Google Scholar
• PouslenAWilliamABlanchardSStructure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)J Comput Aided Mol Des201226443745022527961
   PubMed Web of Science ®Google Scholar
• WilliamADLeeACBlanchardSDiscovery of the macrocycle 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27), 16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphomaJ Med Chem201154134638465821604762
   PubMed Web of Science ®Google Scholar
• HartSGohKCNovotny-DiermayrVSB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignanciesLeukemia201125111751175921691275
   PubMed Web of Science ®Google Scholar
• VerstovsekSMachidaCDeanJPMylntHPacritinib. Inhibitor of tyrosine-protein kinase JAK2, inhibitor of FLT-3, treatment of myelofibrosisDrugs Future2013386375386
   Web of Science ®Google Scholar
• VerstovsekSOdenikeOScottBPhase I dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocytopenia/polycythemia vera myelofibrosis [abstract 3905, ASH]Blood20091141502
   Web of Science ®Google Scholar
• SeymourJFToBGohAFirst report of the phase I study of the novel oral JAK2 inhibitor SB1518 in patients with myelofibrosis [abstract 1144]Haematologica201095Suppl 2472
   Google Scholar
• DeegHJOdenikeOScottBLPhase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis [abstract]J Clin Oncol201129Suppl 15 abstract 6515, ASCO
   Google Scholar
• VerstovsekMDDeegHGOdenikeOPhase 1/2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosisBlood2010 abstract 3082, ASH
   Web of Science ®Google Scholar
• KomrokjiRSSeymourJFRobertsAWResults of a Phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosisBlood2015125172649265525762180
   PubMed Web of Science ®Google Scholar
• Cell TherapeuticsOral pacritinib versus best available therapy to treat myelofibrosis (PAC325) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01773187. NLM identifier: NCT01773187Accessed June 5, 2015
   Google Scholar
• MesaRAEgyedMSzokeAResults of the PERSIST-1 Phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF) [abstract]J Clin Oncol201533 abstract LBA7006, ASCO
   Google Scholar
• Cell TherapeuticsOral pacritinib versus best available therapy to treat myelofibrosis with thrombocytopenia (PAC326) Available from: http://www.clinicaltrials.gov/ct2/show/NCT02055781. NLM identifier: NCT02055781Accessed June 5, 2015
   Google Scholar
• VerstovsekSTamCSWadleighMPhase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitorLeuk Res201438331632224374145
   PubMed Web of Science ®Google Scholar
• SanofiSanofi discontinues clinical development of investigational JAK2 agent fedratinib (SAR302503)Paris, France2013 Available from: http://en.sanofi.com/Images/34935_20131118_JAK-2-FEDRATINIB_en.pdfAccessed June 6, 2015
   Google Scholar
• SantosFPKantarjianHMJainNPhase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia myelofibrosisBlood201011561131113620008298
   PubMed Web of Science ®Google Scholar
• PardananiALabordeRRLashoTLSafety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosisLeukemia20132761322132723459451
   PubMed Web of Science ®Google Scholar
• GileadMomelotinib versus ruxolitinib in subjects with myelofibrosis (simplify 1) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01969838. NLM Identifier: NCT01969838Accessed June 5, 2015
   Google Scholar
• BeerPADelhommeauFLeCouédicJPTwo routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasmBlood2010115142891290020008300
   PubMed Web of Science ®Google Scholar
• PardananiADLevineRLLashoTMPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patientsBlood2006108103472347616868251
   PubMed Web of Science ®Google Scholar